Table 1.
Clinical characteristics of the MG patients included in the study
| All MG | EOMG | LOMG | |
|---|---|---|---|
| Total patients | 98 | 46 | 52 |
| Sex | |||
| F | 60 (61.2%) | 37 (80.4%) | 23 (44.2%) |
| M | 38 (38.8%) | 9 (19.6%) | 29 (55.8%) |
| Mean age (y) | 61.0 (44.2–72.0) | 43.5 (34.0–51.8) | 72.0 (65.8–77.0) |
| Disease duration (y)b | 5.8 (2.0–11.0) | 7.5 (3.4–13.6) | 4.0 (2.0–8.8) |
| MG-ADL | 2 (0–5) | 3 (0–6) | 1 (0–4) |
| MGC | 4 (0–9.75) | 5 (0–11) | 2 (0–7) |
| Thymectomy | 24 (24.5%) | 19 (41.3%) | 5 (9.6%) |
| Thymoma | 14 | 10 | 4 |
| Hyperplasia | 6 | 5 | 1 |
| Immunosuppressive treatments | |||
| Yes | 70 (71.4%) | 34 (73.9%) | 36 (69.2%) |
| No | 28 (28.6%) | 12 (26.1%) | 16 (30.8%) |
| Current treatmenta | |||
| AChEI (only) | 20 (20.4%) | 9 (19.6%) | 11 (21.2%) |
| Prednisone | 53 | 30 | 23 |
| Azathioprine | 29 | 15 | 14 |
| Tacrolimus | 1 | 1 | 0 |
| Rituximab | 3 | 2 | 1 |
| IvIg | 2 | 2 | 0 |
| Mycophenolate mofetil | 5 | 4 | 1 |
| Methotrexate | 8 | 4 | 4 |
Age, disease duration, and MG-ADL are presented as median with interquartile range. Abbreviations: F, female; M, male; y, years; EOMG, early-onset myasthenia gravis; LOMG, late-onset myasthenia gravis; MG-ADL, myasthenia gravis activities of daily living; MGC, Myasthenia Gravis Composite score; AChEI, acetylcholinesterase inhibitors; IvIg; intravenous immunoglobulins.
a
The number of detailed immunosuppressive treatments does not add up to 100% since several patients have a combination of many immunosuppressive agents.
b
EOMG and LOMG significantly differed in disease duration; unpaired t test; p = 0.0007.